Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia

European Journal of Haematology
Alessandra FerrajoliMichael J Keating

Abstract

We evaluated the activity and tolerability of alemtuzumab given as a continuous infusion for 7 d followed by subcutaneous administration for 11 wk as salvage therapy for 10 patients with fludarabine-refractory chronic lymphocytic leukemia. The continuous infusion of alemtuzumab was well tolerated. The typical infusion reaction seen with intravenous alemtuzumab was abolished. Two patients achieved a partial response with an overall response rate of 20%. Alemtuzumab levels were measured in four patients and detectable levels were obtained in three. Clinical activity needs to be confirmed in a larger patient population.

References

Mar 1, 1990·Tissue Antigens·G HaleH Waldmann
Mar 1, 1996·British Journal of Rheumatology·J D IsaacsJ M Johnston
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Jan 17, 2002·Journal of Immunological Methods·Peppy Rebello, Geoff Hale
Aug 12, 2003·Cancer·Alessandra FerrajoliMichael J Keating

❮ Previous
Next ❯

Citations

Dec 5, 2008·Leukemia & Lymphoma·Thomas ElterClemens Wendtner
Jan 15, 2013·Community Oncology·Loretta J Nastoupil, Christopher R Flowers
Feb 3, 2009·British Journal of Haematology·John G Gribben, Michael Hallek
Apr 23, 2013·Therapeutic Advances in Hematology·Jeremy L Warner, Jon E Arnason
Jul 1, 2008·Expert Review of Anticancer Therapy·Tadeusz Robak

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.